



<Date> [complete as appropriate]

Important information for healthcare professionals

Changes to packaging and disposal

alprostadil

Caverject 5, 10 & 20 microgram Powder and Solvent for Solution for Injection PA 822/115/1-3


Dear Healthcare Professional,

Pfizer Healthcare Ireland would like to inform you of the following:

The Caverject packaging has changed from a plastic box to a standard carton. This means that the disposal of the syringe, vial and needles has changed. Sections 3 and 6 of the Patient Information Leaflet (PIL) have been revised to reflect the change in the packaging as follows:

PIL – section 3

6. Changing to the injecting needle



Gently twist the larger needle anticlockwise off the syringe. Discard it carefully in a special “sharps” bin (please refer to **How to throw away the syringe and needle safely**). Please ask your doctor or pharmacist if you are unsure about how to dispose of needles. Remove the smaller injecting needle, (30 gauge) with the yellow end from its package, keeping the cover on. Twist the needle clockwise tightly onto the syringe, then remove the needle cover by pushing it away from the syringe with your thumb and forefinger.

How to throw away the syringe and needle safely

Never throw away needles, vials or syringes with your ordinary household rubbish. When you have finished with a needle you must discard it carefully to prevent accidental injury and so that no-one will be able to use it. Put the needle, syringe and vial into a container for needles called a sharps bin (available from your doctor or pharmacist). Ask your doctor or pharmacist for instructions on how to properly dispose of the sharps bin after use if you are at all unsure.



PIL – section 6

Caverject carton box content are as follows:

In the Caverject box you will find 5 items:

1. One glass vial containing Caverject 5, 10 or 20 micrograms as a white to off-white powder
2. One glass syringe containing 1 mL of a clear solution
3. One larger 22 gauge needle - 1½ inches long with a grey plastic end
4. One small 30 gauge needle - 0.5 inch long with a yellow plastic end
5. Two antiseptic pads

Please ensure that all relevant staff are made aware of the content of this letter and that the information is communicated to patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363.

If you have any questions, please contact Medical Information at the following address: Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24. Phone 1-800 633363 or email: eumedinfo@pfizer.com.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Declan O'Callaghan".

Dr Declan O'Callaghan

Country Medical Director